glp 1 agonist vs metformin Comparative Effects of Glucagon-like Peptide Receptor Agonists and on Glaucoma Risk in Patients with Type 2 Diabetes Metformin decreases liver production of
Description
no major safety concerns were observed
The global obesity treatment market is expanding at unprecedented speed, with sales of weight-loss medications forecast to rise dramatically over the next decade.
A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D
Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide
Liraglutide may protect against dementia. dementiaresearcher.nihr.ac.uk Sauerwein K
For external use only
